Dianthus Therapeutics Price Target Announced at $113.00/Share by Roth Capital

What happened

Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating and announced a price target of $113.00 per share, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A price target is the analyst's estimate of where the stock price could go. The Buy rating signals Roth Capital expects the stock to rise, which may draw attention from investors assessing Dianthus Therapeutics.

Analyst inference

A new analyst rating can influence how investors view a stock's potential. The Buy rating and $113.00 target may affect investor positioning in Dianthus Therapeutics shares, though the article gives no market reaction.

Analyst inference

What to watch

1. Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating and a $113.00 per share price target, as reported in the supplied ratings actions. Confirmed
2. Watch for other analysts to issue their own ratings and price targets for Dianthus Therapeutics, which could change how investors view the stock's expected direction. Analyst inference
3. Watch whether Dianthus Therapeutics shares trade toward the $113.00 target, which would show how investors are responding to the new Buy rating. Analyst inference

Evidence

• Original source link unavailable